Positive Data on Eloctate and Alprolix on Long-term Joint Health, Bleeding in Hemophilia to Be Presented
Treatment with Eloctate and Alprolix improves joint health, bleeding episodes and quality of life of patients with hemophilia, Bioverativ and…
Articles by José Lopes, PhD
Phase 3 Trials Evaluating Further Potential of 2 Treatments for Hemophilia A
Interim results of Phase 3 clinical studies investigating two major challenges in hemophilia — the development of inhibitors (antibodies to…
Catalyst, Korea’s ISU ABXIS Plan Clinical Studies of Coagulation Factor for Hemophilia B
San Francisco-based Catalyst Biosciences has completed toxicology studies of its new drug CB 2679d/ISU304 — a highly potent next-generation coagulation factor…
SPK-9001 Boosts Clotting Factor, Cuts Hemophilia B Bleeding Episodes, Study Shows
All of the hemophilia B patients in an ongoing Phase 1/2 clinical trial of SPK-9001 experienced clotting-factor increases and reductions in…
NovoSeven Counters Bleeding in Children with Hemophilia, Study Shows
NovoSeven stops or slows bleeding in children with hemophilia but is associated with blood clotting, a study of hospital medical records…
Gene Therapy Using Microbubbles Seen to Treat Hemophilia B in Mouse Model
Gene therapy delivered by microbubbles shows promise in treating hemophilia B, a hereditary bleeding disorder caused by the lack of…